Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Shares Traded Last Trade
  -184.00 -2.56% 7,000.00 3,556,818 16:35:12
Bid Price Offer Price High Price Low Price Open Price
6,982.00 6,986.00 7,326.00 6,923.00 7,279.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 18,386.37 1,167.24 77.67 83.2 91,833
Last Trade Time Trade Type Trade Size Trade Price Currency
18:57:27 O 3,500 7,020.204 GBX

Astrazeneca (AZN) Latest News (1)

More Astrazeneca News
Astrazeneca Takeover Rumours

Astrazeneca (AZN) Discussions and Chat

Astrazeneca Forums and Chat

Date Time Title Posts
02/4/202009:48*** AstraZeneca *** 363
26/8/201910:24Alzheimer's can be caught .... It's a transmissible disease103
01/5/201919:48why the fall-
13/2/201911:48AstraZeneca Full Year Results on Thursday-

Add a New Thread

Astrazeneca (AZN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Astrazeneca trades in real-time

Astrazeneca (AZN) Top Chat Posts

Astrazeneca Daily Update: Astrazeneca Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AZN. The last closing price for Astrazeneca was 7,184p.
Astrazeneca Plc has a 4 week average price of 5,871p and a 12 week average price of 5,871p.
The 1 year high share price is 7,948p while the 1 year low share price is currently 5,626p.
There are currently 1,311,904,600 shares in issue and the average daily traded volume is 2,957,663 shares. The market capitalisation of Astrazeneca Plc is £91,833,322,000.
the white house: Exchange rate :1 year ago 1.30Now 1.30Share price up 25 notes
arja: cheshire pets, sorry for delay in answering as I was abroad for a few days . It just means " no overhead resistance" when a share price breaks through to a higher level not seen previously . I notice AZN down in last day or so with disappointing announcement and share prices of drug companies can be volatile I guess as a lot of news flows . i am not sure if USA or UK is LEAD market for this stock .
ayl30: RNS today looks positive. Should help share price trend continue
bluemango: Meanwhile, share price only needs to put on just over 2% more and it will be surpassing all time high of £65.40. Good trials results and new approvals keep flowing through and should eventually be translated into earnings and dividend growth.
bountyhunter: that's one way to reduce any potential initial WTO tariffs/bottlenecks!
nw99: Finally, Sabah Meddings, writing for Sunday Times' 'Inside The City' column, looked at AstraZeneca, with a share price that plunged last week after it revealed its key 'Mystic' cancer drug trial had produced disappointing results.The drugmaker had tried its best to deflect the bad news by highlighting ann $8.5bn partnership with Merck over its Lynparza cancer treatment, as well as positive phase III results for another of its cancer candidates Tagrisso.But investors were having none of it, wiping £10bn off the value of AstraZeneca in a single day.Meddings suggested the City may have overreacted, however, saying the crash could have been exacerbated by uncertainty over the future of the company's chief Pascal Soriot, and pointing out Neil Woodford's decision to continue to back Astra over rival GlaxoSmithKline.Woodford had noted that Astra remained "very attractive" - comments backed up by Citi's 'buy' rating on the stock.Meddings said Astra's shares looked cheap compared to GSK at 22 times earnings - about half of Glaxo's valuation - but added that Astra's value wasn't wildly different to the rest of the sector globally.She said that - Mystic aside - the results were "OK", as revenue fell 11% to $10.5bn in the first half, in line with expectations, and profits still leaping 22% to $1.8bn even after accounting for weak sterling.Meddings said it would take time for other projects to emerge from the lab in an investable state, although ongoing speculation of a potential bid from Novartis would likely "keep a floor" on Astra's price."Therefore, Astra looks like a reasonable each-way bet - and one that pays a dividend."
minerve: My comment from yesterday: "Minerve 27 Jul '17 - 10:46 - 1954 of 1988 0 0 Edit This is oversold IMO. Just looking at TPs, consensus affects on earnings and past share price history I would say a stabilising share price should sit around 4675." Pretty good, huh?
minerve: This is oversold IMO. Just looking at TPs, consensus affects on earnings and past share price history I would say a stabilising share price should sit around 4675.
steeplejack: Well,I guess the analysts have run their adjustments of new discounted cash flow calculations on Mystic accounting for this giant setback/failure.The share price has retreated back to where it was end Feb.A correction of 15% on the day,is fairly unforgiving but understandable.I'm not selling but I'm unprepared to buy into a dead cat bounce or the wishful thinking of a bid.For now,there's consolation in the dividend.
harvester: Share price below indicative offer since not all cash offer and risk of pfizer share price weakening as well as risk of the deal failing . AZN share price closed last night at 4851 up 151 based on suspicious after hours trades . At normal market close the share price was 4676.5 . Big money at stake. Hence bound to be some insider trading going on .
Astrazeneca share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200407 20:47:58